Investor Presentaiton
Update to presentation of non-GAAP financial measures (1)
Royalty acquisition
Update to Adjusted
Cash Flow
($ in millions)
GAAP
Third-party royalty
(approved / development-stage)
Synthetic royalty
(approved)
No change
Non-GAAP
No change
2020
Royalty
Amount
BCX9930
($6)
ACF (prior)
$1,483
ACF (modified)
$1,477
Synthetic royalty
(development-stage)(2)
Change (%)
-0.4%
2021
No change
No change
Royalty
BCX9930
Amount
($103)
pelabresib
No change
Updating financials to include
certain R&D funding payments
($90)
CPI-0209
ACF (prior)
$1,767
BCX9930, pelabresib,
CPI-0209, aficamten
ACF (modified)
$1,573
Change (%)
-11.0%
Examples
Approved: Cabometyx, Tremfya
Development-stage: otilimab,
gantenerumab
Orladeyo, Nurtec
incremental royalty
Amounts may not add due to rounding
1.
ROYALTY PHARMA
2.
General treatment of development-stage funding payments - upfront and milestones in non-GAAP financials is subject to specifics of transaction; for development-stage therapies, treatment
may depend on probability of success, among other factors.
Ongoing R&D funding arrangements paid over time as our counterparty incurs R&D costs and already included in non-GAAP financials; upfront and milestone development-stage funding
payments related to R&D funding arrangements are now included in Adjusted Cash Flow.
109View entire presentation